DNA methylation profiling in Barrett's esophagus and esophageal adenocarcinoma reveals unique methylation signatures and molecular subclasses

Epigenetics

Volumn 6, Issue 12, 2011, Pages 1403-1412

  Kaz, Andrew M ^a,b,c   Wong, Chao Jen ^a   Luo, Yanxin ^a,d,e   Virgin, Jeffrey B ^c   Kay Washington, M ^f   Willis, Joseph E ^g   Leidner, Rom S ^g   Chak, Amitabh ^g   Grady, William M ^a,b  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^d The Second Affiliated Hospital   (China)

^e SUN YAT SEN UNIVERSITY   (China)

^f VANDERBILT UNIVERSITY   (United States)

^g CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Barrett's esophagus; DNA methylation; Esophageal adenocarcinoma; Methylation microarray

Indexed keywords

DNA;

ARTICLE; BARRETT ESOPHAGUS; CPG ISLAND; DNA FINGERPRINTING; DNA METHYLATION; DNA MICROARRAY; EPIGENETICS; ESOPHAGEAL ADENOCARCINOMA; GENE SET ENRICHMENT ANALYSIS; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN;

EID: 83255176203     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.6.12.18199     Document Type: Article

References (52)

1. Spechler SJ. Clinical practice. Barrett's Esophagus. N Engl J Med 2002; 346:836-42; DOI:10.1056/NEJMcp012118.
2. Blot WJ, McLaughlin JK. The changing epidemiology of esophageal cancer. Semin Oncol 1999; 26:2-8
3. BJ, Li X, Galipeau PC, Vaughan TL. Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer 2010; 10:87-101; DOI:10.1038/nrc2773.
4. Galipeau PC, Li X, Blount PL, Maley CC, Sanchez CA, Odze RD, et al. NSAIDs modulate CDKN2A, TP53 and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med 2007; 4:67; DOI:10.1371/journal. pmed.0040067.
5. F, Cardwell C, Cantwell MM, Galway K, Johnston BT, Murray L. The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis. Am J Epidemiol 2008; 168:237-49; DOI:10.1093/ aje/kwn121.
6. Orlando RC. Mucosal Defense in Barrett's Esophagus. In: Sharma P, Ed. Barrett's Esophagus and Esophageal Adenocarcinoma. Oxford: Blackwell Publishing, Ltd. 2006; 60-72.
7. Dixon J, Strugala V, Griffin SM, Welfare MR, Dettmar PW, Allen A, et al. Esophageal mucin: an adherent mucus gel barrier is absent in the normal esophagus but present in columnar-lined Barrett's esophagus. Am J Gastroenterol 2001; 96:2575-83; DOI:10.1111/j.1572-0241.2001.04159.x.
8. Jovov B, Van Itallie CM, Shaheen NJ, Carson JL, Gambling TM, Anderson JM, et al. Claudin-18: a dominant tight junction protein in Barrett's esophagus and likely contributor to its acid resistance. Am J Physiol Gastrointest Liver Physiol 2007; 293:1106-13; DOI:10.1152/ajpgi.00158.2007.
9. M, Mueller J, Walch A, Hofler H. The molecular pathology of Barrett's esophagus. Histol Histopathol 1999; 14:553-9
10. Fléjou JF. Barrett's oesophagus: from metaplasia to dysplasia and cancer. Gut 2005; 54:6-12 DOI:10.1136/gut.2004.041525
11. Reid BJ, Levine DS, Longton G, Blount PL, Rabinovitch PS. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 2000; 95:1669-76.
12. Maley CC, Galipeau PC, Finley JC, Wongsurawat VJ, Li X, Sanchez CA, et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet 2006; 38:468-73; DOI:10.1038/ng1768.
13. Nancarrow DJ, Handoko HY, Smithers BM, Gotley DC, Drew PA, Watson DI, et al. Genome-wide copy number analysis in esophageal adenocarcinoma using high-density single-nucleotide polymorphism arrays. Cancer Res 2008; 68:4163-72; DOI:10.1158/0008-5472.CAN-07-6710.
14. Jenkins GJ, Doak SH, Parry JM, D'Souza FR, Griffiths AP, Baxter JN. Genetic pathways involved in the progression of Barrett's metaplasia to adenocarcinoma. Br J Surg 2002; 89:824-37; DOI:10.1046/j.1365-2168.2002.02107.x.
15. Lai LA, Paulson TG, Li X, Sanchez CA, Maley C, Odze RD, et al. Increasing genomic instability during premalignant neoplastic progression revealed through high resolution array-CGH. Genes Chromosomes Cancer 2007; 46:532-42; DOI:10.1002/ gcc.20435.
16. CC, Galipeau PC, Li X, Sanchez CA, Paulson TG, Reid BJ. Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus. Cancer Res 2004; 64:3414-27; DOI:10.1158/0008-5472.CAN-03-3249.
17. Barrett MT, Sanchez CA, Prevo LJ, Wong DJ, Galipeau PC, Paulson TG, et al. Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet 1999; 22:106-9; DOI:10.1038/8816.
18. Sikkema M, Kerkhof M, Steyerberg EW, Kusters JG, van Strien PM, Looman CW, et al. Aneuploidy and Overexpression of Ki67 and p53 as Markers for Neoplastic Progression in Barrett's Esophagus: A Case- Control Study. Am J Gastroenterol 2009; 104:2673-80.
19. Murray L, Sedo A, Scott M, McManus D, Sloan JM, Hardie LJ, et al. Tp53 and progression from Barrett's metaplasia to oesophageal adenocarcinoma in a UK population cohort. Gut 2006; 55:1390-7; DOI:10.1136/gut.2005.083295.
20. Weston AP, Banerjee SK, Sharma P, Tran TM, Richards R, Cherian R. p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression. Am J Gastroenterol 2001; 96:1355-62; DOI:10.1111/j.1572-0241.2001.03851.x.
21. Cronin J, McAdam E, Danikas A, Tselepis C, Griffiths P, Baxter J, et al. Epidermal Growth Factor Receptor (EGFR) Is Overexpressed in High-Grade Dysplasia and Adenocarcinoma of the Esophagus and May Represent a Biomarker of Histological Progression in Barrett's Esophagus (BE). Am J Gastroenterol 2011; 106:46-56; DOI:10.1038/ajg.2010.433.
22. Jones S, Emmerson P, Maynard J, Best JM, Jordan S, Williams GT, et al. Biallelic germline mutations in MYH predispose to multiple colorectal adenoma and somatic G:C?T:A mutations. Hum Mol Genet 2002; 11:2961-7; DOI:10.1093/ hmg/11.23.2961.
23. Mulero-Navarro S, Esteller M. Epigenetic biomarkers for human cancer: the time is now. Crit Rev Oncol Hematol 2008; 68:1-11; DOI:10.1016/j.critrevonc.2008.03.001.
24. Smith E, De Young NJ, Pavey SJ, Hayward NK, Nancarrow DJ, Whiteman DC, et al. Similarity of aberrant DNA methylation in Barrett's esophagus and esophageal adenocarcinoma. Mol Cancer 2008; 7:75; DOI:10.1186/1476-4598-7-75.
25. Clément G, Braunschweig R, Pasquier N, Bosman FT, Benhattar J. Methylation of APC, TIMP3 and TERT: a new predictive marker to distinguish Barrett's oesophagus patients at risk for malignant transformation. J Pathol 2006; 208:100-7; DOI:10.1002/path.1884.
26. Jin Z, Cheng Y, Gu W, Zheng Y, Sato F, Mori Y, et al. A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus. Cancer Res 2009; 69:4112-5; DOI:10.1158/0008-5472.CAN-09-0028.
27. Tischoff I, Hengge UR, Vieth M, Ell C, Stolte M, Weber A, et al. Methylation of SOCS-3 and SOCS-1 in the carcinogenesis of Barrett's adenocarcinoma. Gut 2007; 56:1047-53; DOI:10.1136/ gut.2006.111633.
28. Hamilton JP, Sato F, Greenwald BD, Suntharalingam M, Krasna MJ, Edelman MJ, et al. Promoter methylation and response to chemotherapy and radiation in esophageal cancer. Clin Gastroenterol Hepatol 2006; 4:701-8; DOI:10.1016/j. cgh.2006.03.007.
29. Shen L, Toyota M, Kondo Y, Lin E, Zhang L, Guo Y, et al. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci USA 2007; 104:18654-9; DOI:10.1073/pnas.0704652104.
30. Hinoue T, Weisenberger DJ, Lange CP, Shen H, Byun HM, Van Den Berg D, et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res 2011.
31. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010; 17:510-22; DOI:10.1016/j.ccr.2010.03.017.
32. N, Li Q, Mohan M, Baylin S, Issa JP. Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res 1998; 58:5489-94.
33. Kwabi-Addo B, Chung W, Shen L, Ittmann M, Wheeler T, Jelinek J, et al. Age-related DNA methylation changes in normal human prostate tissues. Clin Cancer Res 2007; 13:3796-802; DOI:10.1158/1078-0432.CCR-07-0085.
34. Eads CA, Lord RV, Kurumboor SK, Wickramasinghe K, Skinner ML, Long TI, et al. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. Cancer Res 2000; 60:5021-6.
35. Eads CA, Lord R, Wickramasinghe K, Long T, Kurumboor S, Bernstein L, et al. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res 2001; 61:3410-8.
36. Eads CA, Lord RV, Wickramasinghe K, Long TI, Kurumboor SK, Bernstein L, et al. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res 2001; 61:3410-8.
37. Zou H, Osborn NK, Harrington JJ, Klatt KK, Molina JR, Burgart LJ, et al. Frequent methylation of eyes absent 4 gene in Barrett's esophagus and esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2005; 14:830-4; DOI:10.1158/1055-9965.EPI-04-0506.
38. Jin Z, Cheng Y, Olaru A, Kan T, Yang J, Paun B, et al. Promoter hypermethylation of CDH13 is a common, early event in human esophageal adenocarcinogenesis and correlates with clinical risk factors. Int J Cancer 2008; 123:2331-6; DOI:10.1002/ ijc.23804.
39. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999; 96:8681-6; DOI:10.1073/ pnas.96.15.8681.
40. Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer 2004; 4:988-93; DOI:10.1038/nrc1507.
41. Enjuanes A, Fernàndez V, Hernández L, Navarro A, Beà S, Pinyol M, et al. Identification of Methylated Genes Associated with Aggressive Clinicopathological Features in Mantle Cell Lymphoma. PLoS ONE 2011; 6:19736; DOI:10.1371/journal. pone.0019736.
42. Chen PC, Tsai MH, Yip S, Jou YC, Ng CF, Chen Y, et al. Distinct DNA methylation epigenotypes in bladder cancer from different Chinese sub-populations and its implication in cancer detection using voided urine. BMC Med Genomics 2011; 4:45; DOI:10.1186/1755-8794-4-45.
43. Fang F, Turcan S, Rimner A, Kaufman A, Giri D, Morris LGT, et al. Breast Cancer Methylomes Establish an Epigenomic Foundation for Metastasis. Sci Transl Med 2011; 3:25; DOI:10.1126/ scitranslmed.3001875.
44. Zhang Y, Wang R, Song H, Huang G, Yi J, Zheng Y, et al. Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer. Cancer Lett 2011; 303:21-8; DOI:10.1016/j. canlet.2010.12.011.
45. Park SY, Kook M, Kim Y, Cho NY, Jung N, Kwon HJ, et al. CpG island hypermethylator phenotype in gastric carcinoma and its clinicopathological features. Virchows Arch 2010; 457:415-22; DOI:10.1007/s00428-010-0962-0.
46. Wu LM, Zhang F, Zhou L, Yang Z, Xie HY, Zheng SS. Predictive value of CpG island methylator phenotype for tumor recurrence in hepatitis B virus-associated hepatocellular carcinoma following liver transplantation. BMC Cancer 2010; 10:399; DOI:10.1186/1471-2407-10-399.
47. Tanemura A, Terando AM, Sim MS, van Hoesel AQ, de Maat MFG, Morton DL, et al. CpG Island Methylator Phenotype Predicts Progression of Malignant Melanoma. Clin Cancer Res 2009; 15:1801-7; DOI:10.1158/1078-0432.CCR-08-1361.
48. R, Gentleman R, Huber W. Independent filtering increases detection power for high-throughput experiments. Proc Natl Acad Sci USA 2010; 107:9546-51; DOI:10.1073/ pnas.0914005107.
49. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004; 3:3.
50. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate in behavior genetics research. Behav Brain Res 2001; 125:279-84; DOI:10.1016/S0166-4328(01)00297-2.
51. Falcon S, Gentleman R. Using GOstats to test gene lists for GO term association. Bioinformatics 2007; 23:257-8; DOI:10.1093/bioinformatics/ btl567.
52. Bock C, Reither S, Mikeska T, Paulsen M, Walter J, Lengauer T. BiQ Analyzer: visualization and quality control for DNA methylation data from bisulfite sequencing. Bioinformatics 2005; 21:4067-8; DOI:10.1093/bioinformatics/ bti652.